Anika Therapeutics (ANIK) EBIT Margin (2016 - 2025)
Historic EBIT Margin for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to 11.62%.
- Anika Therapeutics' EBIT Margin fell 113500.0% to 11.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.99%, marking a year-over-year decrease of 344900.0%. This contributed to the annual value of 4.25% for FY2024, which is 49500.0% down from last year.
- According to the latest figures from Q3 2025, Anika Therapeutics' EBIT Margin is 11.62%, which was down 113500.0% from 14.81% recorded in Q2 2025.
- Anika Therapeutics' 5-year EBIT Margin high stood at 24.07% for Q2 2021, and its period low was 852.09% during Q4 2023.
- In the last 5 years, Anika Therapeutics' EBIT Margin had a median value of 9.69% in 2022 and averaged 83.55%.
- Per our database at Business Quant, Anika Therapeutics' EBIT Margin crashed by -5630900bps in 2022 and then surged by 8497800bps in 2024.
- Quarter analysis of 5 years shows Anika Therapeutics' EBIT Margin stood at 25.47% in 2021, then plummeted by -2211bps to 588.55% in 2022, then tumbled by -45bps to 852.09% in 2023, then soared by 100bps to 2.3% in 2024, then plummeted by -404bps to 11.62% in 2025.
- Its EBIT Margin was 11.62% in Q3 2025, compared to 14.81% in Q2 2025 and 16.37% in Q1 2025.